Page 38 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Role of common CXC chemokines in NAFLD

63. Ibrahim SH, Hirsova P, Tomita K, et al. Mixed lineage differentiation-associated gene 5 positively modulates TNF-
kinase 3 mediates release of C-X-C motif ligand 10-bearing α-induced CXCL10 expression in cultured HuH-7 and HLE
chemotactic extracellular vesicles from lipotoxic Cells. Inflammation. 2019;42(6):2095-2104.
hepatocytes. Hepatology. 2016;63(3):731-744.
doi: 10.1007/s10753-019-01073-3
doi: 10.1002/hep.28252
74. Harrison SA, Bedossa P, Guy CD, et al. A phase 3,
64. Yang Z, Han X, Wang K, Fang J, Wang Z, Liu G. Combined randomized, controlled trial of resmetirom in NASH with
with multiplex and network analysis to reveal the key genes liver fibrosis. N Engl J Med. 2024;390(6):497-509.
and mechanisms of nonalcoholic fatty liver disease. Int
Immunopharmacol. 2023;123:110708. doi: 10.1056/NEJMoa2309000
75. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety
doi: 10.1016/j.intimp.2023
and efficacy in patients with non-alcoholic steatohepatitis
65. Xu Z, Zhang X, Lau J, Yu J. C-X-C motif chemokine 10 in (LEAN): a multicentre, double-blind, randomised, placebo-
non-alcoholic steatohepatitis: Role as a pro-inflammatory controlled phase 2 study. Lancet. 2016;387(10019):679-690.
factor and clinical implication. Expert Rev Mol Med.
2016;18:e16. doi: 10.1016/S0140-6736(15)00803-X
76. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-
doi: 10.1017/erm.2016.16
controlled trial of subcutaneous semaglutide in nonalcoholic
66. Dali-Youcef N, Vix M, Costantino F, et al. Interleukin-32 steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
contributes to human nonalcoholic fatty liver disease and
insulin resistance. Hepatol Commun. 2019;3(9):1205-1220. doi: 10.1056/NEJMoa2028395
doi: 10.1002/hep4.1396 77. Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized,
controlled trial of the FGF21 analogue pegozafermin in
67. Chang CC, Wu CL, Su WW, et al. Interferon gamma-induced NASH. N Engl J Med. 2023;389(11):998-1008.
protein 10 is associated with insulin resistance and incident
diabetes in patients with nonalcoholic fatty liver disease. Sci doi: 10.1056/NEJMoa2304286
Rep. 2015;5:10096. 78. Shih PH, Shiue SJ, Chen CN, et al. Fucoidan and fucoxanthin
doi: 10.1038/srep10096 attenuate hepatic steatosis and inflammation of NAFLD
through modulation of leptin/adiponectin axis. Mar Drugs.
68. Tomita K, Freeman BL, Bronk SF, et al. CXCL10-mediates 2021;19(3):148.
macrophage, but not other innate immune cells-associated
inflammation in murine nonalcoholic steatohepatitis. Sci doi: 10.3390/md19030148
Rep. 2016;6:28786. 79. Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a
doi: 10.1038/srep28786 PPAR-α/γ agonist, for treatment of NAFLD: A randomized
controlled double-blind phase 2 trial. Hepatology.
69. Maina V, Sutti S, Locatelli I, et al. Bias in macrophage 2021;74(4):1809-1824.
activation pattern influences non-alcoholic steatohepatitis
(NASH) in mice. Clin Sci (Lond). 2012;122(11):545-553. doi: 10.1002/hep.31843
doi: 10.1042/CS20110366 80. Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V,
et al. Cenicriviroc lacked efficacy to treat liver fibrosis in
70. Deiuliis JA, Oghumu S, Duggineni D, et al. CXCR3 nonalcoholic steatohepatitis: AURORA phase III randomized
modulates obesity-induced visceral adipose inflammation study. Clin Gastroenterol Hepatol. 2024;22(1):124-134.e1.
and systemic insulin resistance. Obesity (Silver Spring).
2014;22(5):1264-1274. doi: 10.1016/j.cgh.2023.04.003
doi: 10.1002/oby.20642 81. Gart E, Van Duyvenvoorde W, Caspers MPM, et al.
Intervention with isoleucine or valine corrects
71. Zhou C, Shen Z, Shen B, et al. FABP4 in LSECs promotes hyperinsulinemia and reduces intrahepatic diacylglycerols,
CXCL10-mediated macrophage recruitment and M1 liver steatosis, and inflammation in Ldlr-/-.Leiden
polarization during NAFLD progression. Biochim Biophys mice with manifest obesity-associated NASH. FASEB J.
Acta Mol Basis Dis. 2023;1869(7):166810. 2022;36(8):e22435.
doi: 10.1016/j.bbadis.2023.166810
doi: 10.1096/fj.202200111R
72. Zhang X, Wu WK, Xu W, et al. C-X-C motif chemokine 10 82. Yang YM, Fukui M, Wang Z, Miao F, Karriker MJ, Seki E.
impairs autophagy and autolysosome formation in non- Interventional potential of recombinant feline hepatocyte
alcoholic steatohepatitis. Theranostics. 2017;7(11):2822-2836. growth factor in a mouse model of non-alcoholic
doi: 10.7150/thno.19068 steatohepatitis. Front Endocrinol (Lausanne). 2018;9:378.
73. Kawaguchi S, Sakuraba H, Haga T, et al. Melanoma doi: 10.3389/fendo.2018.00378

Volume 9 Issue 3 (2025) 30 doi: 10.36922/ejmo.8383